Literature DB >> 11076661

Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.

K H Yeh1, S H Yeh, C H Hsu, T M Wang, I F Ma, A L Cheng.   

Abstract

We have recently demonstrated that HDFL (high-dose 5-FU 2600 mg m-2 week-1 and leucovorin 500 mg m-2 week-1, weekly 24-h infusion) is highly active in the treatment of gastric cancer. To further clarify the possible mechanism underlying the improved activity of HDFL compared with conventional 5-FU regimens, we conducted in vitro studies examining the effect of these regimens on the differential regulation of thymidylate synthase (TS) in NCI-N87, a human gastric cancer cell line. The expected serum concentrations of 5-FU are 100-200 mM (lasting for less than 30 min) and 5-10 mM (lasting for 24 h) for the conventional 5-FU regimens (bolus injection or short intravenous infusion of 5-FU 370-500 mg m-2) and the HDFL regimens, respectively. Western blot analysis revealed that 24-h exposure of NCI-N87 to 2.5-10.0 mM of 5-FU resulted in a dose-dependent depletion of free TS, lasting for more than 24 h. In contrast, 30-min exposure of NCI-N87 to 200 mM of 5-FU resulted in a less than 12-h depletion of free TS. Moreover, 24-h exposure to 5-FU resulted in a higher S-phase blockade and enhanced cytotoxicity. In both modes of 5-FU treatment, the initial rapid depletion of free TS was accompanied by a rapid increment of a higher-molecular-weight TS molecule, suggesting that rapid formation of the ternary complex was the key mechanism of 5-FU action during this period. Northern blot analysis showed that the steady-state mRNA of TS was not affected by either of the schedules. We conclude that 24-h exposure of gastric cancer cells to low concentration of 5-FU resulted in better suppression of free TS, a higher degree of S-phase blockade, and enhanced cytotoxicity compared to 30-min exposure to high concentration of 5-FU. These in vitro results may help explain the improved clinical efficacy of HDFL regimens compared to conventional 5-FU regimens. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076661      PMCID: PMC2363429          DOI: 10.1054/bjoc.2000.1456

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.

Authors:  P G Johnston; J C Drake; J Trepel; C J Allegra
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

2.  Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue.

Authors:  P G Johnston; C M Liang; S Henry; B A Chabner; C J Allegra
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts.

Authors:  L G Navalgund; C Rossana; A J Muench; L F Johnson
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

6.  A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.

Authors:  B Ardalan; L Chua; E M Tian; R Reddy; K Sridhar; P Benedetto; S Richman; A Legaspi; S Waldman; L Morrell
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

7.  Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.

Authors:  E Chu; J C Drake; D M Koeller; S Zinn; C A Jamis-Dow; G C Yeh; C J Allegra
Journal:  Mol Pharmacol       Date:  1991-02       Impact factor: 4.436

8.  Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.

Authors:  E Chu; D M Koeller; J L Casey; J C Drake; B A Chabner; P C Elwood; S Zinn; C J Allegra
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

9.  A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.

Authors:  J L Grem; N McAtee; R F Murphy; F M Balis; S M Steinberg; J M Hamilton; J M Sorensen; O Sartor; B S Kramer; L J Goldstein
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

10.  Role of E2F-1 in chemosensitivity.

Authors:  D Banerjee; B Schnieders; J Z Fu; D Adhikari; S C Zhao; J R Bertino
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

View more
  9 in total

1.  Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma.

Authors:  Xiao-yan Tang; You-qing Zhu; Wen-hui Tao; Bai Wei; Xiao-ling Lin
Journal:  Postgrad Med J       Date:  2007-05       Impact factor: 2.401

2.  Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma.

Authors:  Jing Wang; Zi-Rong Yang; Wei-Guo Dong; Ji-Xiang Zhang; Xu-Feng Guo; Jia Song; Shi Qiu
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

3.  Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study.

Authors:  I P Popov; S B Jelić; Z V Krivokapić; S D Jezdić; P M Pesko; M T Micev; D R Babić
Journal:  Med Oncol       Date:  2007-11-01       Impact factor: 3.064

4.  Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.

Authors:  Chiun Hsu; Ying-Chun Shen; Chia-Chi Cheng; Ann-Lii Cheng; Fu-Chang Hu; Kun-Huei Yeh
Journal:  Gastric Cancer       Date:  2012-05-12       Impact factor: 7.370

5.  Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer.

Authors:  K H Yeh; Y S Lu; C H Hsu; J F Lin; H J Chao; T C Huang; C Y Chung; C S Chang; C H Yang; A L Cheng
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

6.  Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.

Authors:  Y Chao; K H Yeh; C J Chang; L T Chen; T Y Chao; M F Wu; C S Chang; J Y Chang; C Y Chung; W Y Kao; R K Hsieh; A L Cheng
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

7.  Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.

Authors:  Bhumsuk Keam; Seock-Ah Im; Sae-Won Han; Hye Seon Ham; Min A Kim; Do-Youn Oh; Se-Hoon Lee; Jee Hyun Kim; Dong-Wan Kim; Tae-You Kim; Dae Seog Heo; Woo Ho Kim; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2008-05-27       Impact factor: 4.430

8.  Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.

Authors:  C Hsu; Y-C Shen; C-H Yang; K-H Yeh; Y-S Lu; C-H Hsu; H-T Liu; C-C Li; J-S Chen; C-Y Wu; A-L Cheng
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

9.  Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.

Authors:  Ching-Yun Hsieh; Ming-Yuh Lein; Shih-Neng Yang; Yao-Ching Wang; Yin-Jun Lin; Chen-Yuan Lin; Chun-Hung Hua; Ming-Hsul Tsai; Ching-Chan Lin
Journal:  BMC Cancer       Date:  2020-09-01       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.